Shots:
- Envisagenics has entered a multi-year research collaboration & option agreement with BI to validate tumor-specific targets for developing first-in-class precision therapies for solid tumors, using Envisagenics’ AI-powered SpliceCore platform
- Collaboration builds on targets identified through SpliceCore to validate their potential across ADCs, TCEs & multispecific Abs, with BI having an option to exclusively license selected targets for further development and commercialization upon successful completion
- As per the deal, Envisagenics will receive >$1B, incl. an upfront payment, research funding, option fees & development, regulatory & commercial milestones, plus royalties on future product sales
Ref: Globenewswire | Image: Envisagenics & BI | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
